[144] Travere Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Travere Therapeutics, Inc. (TVTX) dated April 6, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $330,000. These shares were acquired on April 6, 2026, through a stock option exercise and payment was made in cash.
Travere Therapeutics (TVTX) seeks approval to add 3M shares to 2018 equity plan
Travere Therapeutics (TVTX) is seeking stockholder approval at its 2026 Annual Meeting to increase the number of shares authorized for its 2018 Equity Incentive Plan by 3 million. This increase is deemed crucial for attracting, retaining, and motivating employees to support the company's growth, including the commercial launch of FILSPARI® (sparsentan) for IgAN and potential approval for FSGS. The proposal emphasizes that equity awards are essential for aligning employee incentives with stockholder interests, especially given the company's significant business expansion and competitive biopharmaceutical labor market.
Palisades Investment Partners LLC Invests $5.26 Million in Travere Therapeutics, Inc. $TVTX
Palisades Investment Partners LLC recently acquired a new stake of 137,768 shares, worth $5.26 million, in Travere Therapeutics (NASDAQ:TVTX) during the fourth quarter, making it their 22nd largest holding. Despite this institutional investment, the company has seen significant insider selling, with the CFO and CAO disposing of shares totaling nearly $9.5 million in the last 90 days. Analysts currently rate TVTX as a "Moderate Buy" with an average price target of $39, significantly higher than its current trading price of around $30.44.
Travere Therapeutics (TVTX) CEO sells 60K shares after option exercise
Travere Therapeutics CEO Eric M. Dube exercised stock options for 60,000 shares at $15.46 each on April 1, 2026, and subsequently sold all 60,000 shares in the open market for a total of $1,855,839. These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted in June 2025. Following these sales, Dube directly holds 432,886 shares of Travere common stock.
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube sold 60,000 shares of the company's stock on April 1st for $1.856 million, reducing his stake by 12.17%. The sale was pre-arranged under a Rule 10b5-1 plan. Despite this insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts with a target price of $39.00, and institutional investors like State Street and Wellington have recently increased their positions.
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock
Travere Therapeutics (NASDAQ:TVTX) Director Elizabeth Reed sold 10,000 shares of the company's stock for $300,000 on April 1st, reducing her stake by 8.68%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, TVTX shares fell about 3.1% to $30.44 with below-average volume, while analysts maintain a "Moderate Buy" consensus with an average target price of $39.
Travere (NASDAQ: TVTX) CLO exercises options, pre-planned sale of 10K shares
Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised employee stock options for 10,000 shares at $15.46 per share and subsequently sold those 10,000 shares at $30.00 per share. This transaction, executed on April 1, 2026, was conducted under a pre-planned Rule 10b5-1 trading plan adopted on June 16, 2025. After the sale, Reed directly holds 105,211 shares of Travere Therapeutics common stock.
Travere therapeutics chief legal officer sells $300k in TVTX stock
Elizabeth E. Reed, Chief Legal Officer of Travere Therapeutics, sold 10,000 shares of TVTX common stock for $300,000 on April 1, 2026, while also exercising options to acquire 10,000 shares. The sale was part of a pre-arranged trading plan. Separately, the FDA extended its review of Travere's Filspari sNDA, creating regulatory uncertainty for the company.
Travere Therapeutics (TVTX) Is Up 14.0% After FDA Focus Shifts To FILSPARI FSGS Label Expansion - Has The Bull Case Changed?
Travere Therapeutics (TVTX) stock rose 14.0% due to an upcoming FDA PDUFA decision on April 13, 2026, for FILSPARI's label expansion in focal segmental glomerulosclerosis (FSGS), alongside an analyst upgrade to a Buy rating. The article emphasizes FILSPARI's central role in Travere's strategy and the potential impact of the FDA decision on its revenue while acknowledging the risks of relying on a single kidney franchise. The company's future projections include significant revenue and earnings growth by 2028, leading to a fair value estimate of $42.36.
(TVTX) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Travere Therapeutics Inc. (TVTX), highlighting strong near-term sentiment that could lead to a long-term positive bias. It outlines distinct trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The report also mentions an exceptional risk-reward short setup targeting 18.7% downside versus 0.3% risk.
TVTX (NASDAQ: TVTX) files Form 144 for 60,000-share sale
Travere Therapeutics, Inc. (NASDAQ: TVTX) has filed a Form 144, indicating an intended sale of 60,000 shares of common stock on April 1, 2026, through a cash transaction. The filing details that these shares originated from an option granted on January 31, 2020. This document also discloses several prior sales by Eric M. Dube, accounting for 8,135, 51,865, 100,087, and 60,000 shares between January 23, 2026, and February 20, 2026.
Elizabeth Reed registers sale of 10,000 TVTX shares (TVTX) via option exercise
Elizabeth Reed has filed a Form 144, indicating a proposed sale of 10,000 shares of Travere Therapeutics (TVTX) common stock, resulting from a stock option exercise on April 1, 2026. The filing also details several previous dispositions by Reed in early 2026, including sales of 10,000 shares on March 16 for $280,861 and on February 17 for $278,317, among others. The value listed for the current 10,000 shares to be sold is $300,000.
Hennion & Walsh Asset Management Inc. Increases Position in Travere Therapeutics, Inc. $TVTX
Hennion & Walsh Asset Management Inc. significantly increased its stake in Travere Therapeutics (NASDAQ:TVTX) by 169.6% in the fourth quarter, holding 99,229 shares valued at $3.79 million. Despite this institutional buying, company insiders have recently sold a substantial amount of stock, totaling 234,543 shares worth $7.37 million. Analysts maintain a "Moderate Buy" consensus rating for Travere Therapeutics with a target price of $38.38.
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback
Travere Therapeutics (TVTX) has experienced a recent share price pullback, with shares down 8.5% over the past month and 27.7% over three months, despite a strong 52.1% total shareholder return over the past year. The company, focused on therapies for rare kidney and metabolic diseases, is currently sitting below analyst targets and intrinsic estimates, and one narrative suggests it is 35.7% undervalued with a fair value of $42.36 per share. This valuation hinges on rapid revenue expansion, margin improvement, and future earnings, particularly driven by its product FILSPARI.
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback
Travere Therapeutics (TVTX) has experienced a recent share price pullback of 8.5% over the past month and 27.7% over the last three months, despite a strong 52.1% return over the past year. The company, which focuses on rare kidney and metabolic diseases, is currently valued at $42.36 per share by analysts, suggesting it is 35.7% undervalued compared to its last close of $27.25. This valuation largely depends on the success of its drug FILSPARI and continued financial improvements, though risks like competition and potential underperformance of FILSPARI exist.
Tudor Investment Corp Cuts Stake in Travere Therapeutics
Tudor Investment Corp has significantly reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 52.5% in the third quarter of 2025. The hedge fund now owns 95,747 shares, a move that could signal concerns about Travere Therapeutics' future performance or a portfolio reallocation by the prominent investor. This reduction in exposure from a major institutional investor suggests broader concerns, prompting other investors to watch for similar actions.
Tudor Investment Corp ET AL Cuts Stake in Travere Therapeutics, Inc. $TVTX
Tudor Investment Corp ET AL significantly reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 52.5% in the third quarter, selling 105,761 shares and retaining 95,747 shares valued at $2.29 million. Despite this, analysts maintain a broadly positive outlook on TVTX, with an average price target of $38.38, implying substantial upside from its current share price of approximately $27.25. Insider selling has also been noted, with 234,543 shares worth $7.37 million offloaded in the past 90 days.
Is Travere Therapeutics (TVTX) Pricing Look Out Of Step With DCF And Sales Metrics
Simply Wall St analyzed Travere Therapeutics (TVTX) and concluded that its current share price of $27.92 appears significantly undervalued based on a Discounted Cash Flow (DCF) analysis, which estimates an intrinsic value of $122.20 per share. The company also trades at a P/S ratio of 5.25x, which is below the biotech industry average and its proprietary "Fair Ratio" of 5.81x, further suggesting undervaluation. The analysis focuses on long-term fundamental data, indicating a wide valuation gap for TVTX.
JPMorgan Chase Cuts Travere Therapeutics Price Target
JPMorgan Chase & Co. has lowered its price target for Travere Therapeutics (NASDAQ:TVTX) from $44.00 to $41.00, while maintaining an 'overweight' rating on the biopharmaceutical company. This adjustment reflects ongoing research and development efforts and market uncertainties, but JPMorgan Chase remains optimistic about Travere Therapeutics' long-term potential in developing therapies for rare kidney and genetic disorders.
Vanguard disaggregates holdings; reports 0 TVTX shares (Vanguard)
Vanguard has filed a SCHEDULE 13G/A, reporting 0 shares beneficially owned in Travere Therapeutics Inc (TVTX), representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries and divisions will now report their holdings separately in reliance on SEC Release No. 34-39538. The filing clarifies that The Vanguard Group no longer has, or is deemed to have, beneficial ownership over these securities.
Travere Therapeutics, Inc. $TVTX Shares Purchased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in Travere Therapeutics (NASDAQ:TVTX) by 347.5% in the fourth quarter, now owning 417,742 shares valued at approximately $15.96 million. This institutional buying activity contrasts with recent insider selling totaling $7.37 million. Despite insider sales, analysts maintain a "Moderate Buy" rating with a consensus price target near $38.38 for the biopharmaceutical company.
Travere Therapeutics price target lowered to $41 from $44 at JPMorgan
JPMorgan has lowered its price target for Travere Therapeutics (TVTX) to $41 from $44, while maintaining an Overweight rating on the shares. This adjustment comes as the firm updates its models for small-cap biotech companies. The report also highlights recent related news, including Citi's "upside 90-day catalyst watch" on Travere Therapeutics.
Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics
Citi has initiated an "upside 90-day catalyst watch" on Travere Therapeutics (TVTX), maintaining a Buy rating and a $48 price target. The firm anticipates FDA approval for Filspari for focal segmental glomerulosclerosis by April 13, believing the current stock price does not reflect this opportunity. This news highlights potential growth for Travere Therapeutics based on forthcoming regulatory decisions.
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Volatility
Travere Therapeutics (TVTX) has experienced significant share price volatility, with a 32.1% year-to-date decline despite a 30.7% total return over the past year. The current share price of US$26.84 is considered undervalued compared to a narrative-driven fair value of US$42.36, largely due to the potential expansion of FILSPARI's label for FSGS. Investors are encouraged to assess the data and risks independently to determine if this represents a discount opportunity or if market expectations already reflect future growth challenges.
Is Travere Therapeutics (TVTX) Pricing Signal An Opportunity After Recent Share Price Pullback?
Travere Therapeutics (TVTX) has seen mixed stock performance but is identified as undervalued by Simply Wall St's analysis. Both a Discounted Cash Flow (DCF) model and a Price-to-Sales (P/S) ratio analysis suggest the stock is undervalued, specifically by 77.2% based on DCF, with an intrinsic value of $121.33 per share compared to its current price of $27.72. The article encourages investors to delve deeper into valuation narratives to align with their own assumptions about the company's future performance.
TVTX SEC Filings - Travere Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Travere Therapeutics (TVTX) SEC filings, including 10-K, 10-Q, and 8-K reports, offering insights into regulatory documents, financial results, and corporate updates. Recent filings highlight insider stock sales by CEO Eric M. Dube and Chief Legal Officer Elizabeth E. Reed, as well as an FDA extension for FILSPARI's sNDA review. It also mentions FMR LLC's 11.7% stake in the company.
TVTX SEC Filings - Travere Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Travere Therapeutics Inc. (TVTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. Recent filings detail financial results, regulatory developments regarding FILSPARI, and insider stock transactions by key executives. Stock Titan enhances these filings with AI-powered summaries to help investors quickly understand critical information.
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025
Travere Therapeutics (TVTX) has reported a significant 144% annual growth in sales for its drug Filspari in 2025. This strong performance indicates a robust market adoption and potential for the company's financial outlook. The detailed financial results were released for the full year 2025.
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock
Travere Therapeutics (NASDAQ:TVTX) insider Elizabeth Reed recently sold 10,000 shares of the company's stock for $280,900, decreasing her position by 8.68%. Following the sale, Reed now owns 105,211 shares valued at approximately $2.95 million. The stock traded down 2.9% on Wednesday, and analysts currently have a "Moderate Buy" rating with an average price target of $38.17.
Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares
Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised employee stock options for 10,000 shares at $19.08 per share and subsequently sold those 10,000 shares at a weighted average price of $28.0861. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following these actions, Reed directly holds 105,211 shares of Travere Therapeutics common stock.
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025
Travere Therapeutics (TVTX) has announced a significant 144% annual growth in sales for its drug Filspari in 2025. This strong performance highlights the therapeutic's increasing market penetration and adoption. The company's financial results reflect a successful year for the treatment.
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
HC Wainwright has initiated coverage on Travere Therapeutics, Inc. (TVTX) with a "Buy" rating. This positive outlook is primarily driven by the significant breakthroughs associated with the company's drug, FILSPARI. This development suggests a strong belief in FILSPARI's market potential and its impact on Travere Therapeutics' future performance.
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX
Cinctive Capital Management LP disclosed a new position in Travere Therapeutics (NASDAQ:TVTX), purchasing 94,656 shares valued at approximately $2.26 million. Several other institutional investors also adjusted their holdings in the biopharmaceutical company. Analysts have issued a "Moderate Buy" consensus rating for Travere Therapeutics with an average target price of $38.17.
[144] Travere Therapeutics, Inc. SEC Filing
Elizabeth Reed submitted a Form 144 indicating a proposed sale of 10,000 common shares of Travere Therapeutics, Inc. valued at $278,861.00, through a stock option exercise on March 16, 2026. This filing also details previous sales by Ms. Reed totaling over $878,000 across January and February 2026. The Form 144 is a routine notice for issuer-side sales and includes specifics about the securities, acquisition details, and past transactions.
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC
Apis Capital Advisors LLC recently acquired 166,000 shares of Travere Therapeutics (TVTX) in Q3, valued at approximately $3.97 million, making it their 25th largest holding. Despite this institutional buying, the article notes significant insider selling, with CEO Eric M. Dube and other insiders collectively selling over 300,000 shares worth more than $10 million in the past 90 days. Analyst sentiment remains generally positive, with a "Moderate Buy" consensus and an average target price of $38.17.
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall
Travere Therapeutics reported strong Q4 and full-year results for 2026, driven by FILSPARI sales and an expected $25 million milestone from Mirum Pharmaceuticals. This performance highlights the growing importance of its rare kidney disease franchise, although the company still faces binary risk surrounding the upcoming FDA decision on FILSPARI for FSGS. Investors are now evaluating how these positive updates, alongside the extended FDA review, will influence future expectations and Travere's investment narrative.
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall
Travere Therapeutics reported strong fourth-quarter and full-year results for 2026, driven by robust U.S. net product sales of FILSPARI and an anticipated US$25 million milestone from Mirum Pharmaceuticals. This performance reinforces the importance of Travere's rare kidney disease franchise to its revenue. While these results provide some financial buffer, the company still faces significant regulatory risk with the upcoming FDA decision on FILSPARI for FSGS.
Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment
Travere Therapeutics (TVTX) is gaining attention due to strong FILSPARI sales growth and an anticipated US$25 million milestone payment from Mirum Pharmaceuticals. Despite a recent share price decline, the company's financial position is strengthening, with analysts valuing the stock at US$42.36, suggesting it is currently undervalued. This report advises investors to evaluate the risks and rewards, including FILSPARI's market standing and the review process for FSGS.
Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment
Travere Therapeutics (TVTX) is gaining attention due to strong FILSPARI sales growth and an expected US$25 million milestone payment from Mirum Pharmaceuticals in early 2026. Despite a negative year-to-date share price return, the company shows annual revenue growth and improved net income, trading at a 47% discount to analyst targets. Its fair value is assessed at $42.36 per share, contingent on FILSPARI's market performance and the FSGS review process.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Piper Sandler has increased its price target for Travere Therapeutics (TVTX) from $35 to $38, maintaining a Neutral rating, leading to an adjusted upside potential of almost 40%. This adjustment follows the company's strong fourth-quarter earnings, where it reported $126.6 million in U.S. net product sales and a net income of $2.7 million for the quarter, largely driven by FILSPARI sales growth. Travere Therapeutics focuses on developing therapies for rare kidney and metabolic diseases.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Piper Sandler has increased its target price for Travere Therapeutics (TVTX) from $35 to $38, maintaining a Neutral rating, in an adjustment following fourth-quarter pre-releases. This comes after Travere Therapeutics reported strong Q4 2025 earnings with U.S. net product sales of $126.6 million and net income of $2.7 million, significantly boosted by FILSPARI sales. The company specializes in therapies for rare kidney and metabolic diseases and anticipates further cash elevation in H1 2026.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Piper Sandler has increased its target price for Travere Therapeutics (TVTX) from $35 to $38, maintaining a Neutral rating on the stock. This adjustment followed Travere Therapeutics' strong fourth-quarter earnings report, which showed significant growth in U.S. net product sales, largely driven by FILSPARI, and a move from a net loss to a net income compared to the previous year. The company also anticipates further cash and equivalents growth with an upcoming milestone payment.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Piper Sandler has increased its target price for Travere Therapeutics (TVTX) from $35 to $38 while maintaining a Neutral rating. This adjustment follows the company's strong fourth-quarter earnings report, which showed significant growth in U.S. net product sales and a return to net income. Travere Therapeutics is focused on developing therapies for rare kidney and metabolic diseases.
Kentucky Teachers Retirement System Invests $732,000 in Travere Therapeutics
The Teachers Retirement System of The State of Kentucky has invested $732,000 in Travere Therapeutics, Inc. by purchasing 30,635 shares in the third quarter of 2026. This investment highlights growing institutional interest in Travere, a biopharmaceutical company focused on developing treatments for rare kidney and genetic disorders. Other institutional investors also adjusted their holdings in the company during the same period.
Travere Therapeutics, Inc. $TVTX Shares Sold by GW&K Investment Management LLC
GW&K Investment Management LLC significantly reduced its stake in Travere Therapeutics (NASDAQ:TVTX) by 58.3% in the third quarter of 2025, selling over 164,000 shares. Despite this, other major institutions like Vanguard and Adage Capital Partners increased their holdings in the biopharmaceutical company. Meanwhile, insiders have been net sellers in recent months, offloading shares worth over $10 million.
Royce & Associates Reduces Stake in Travere Therapeutics
Royce & Associates LP has significantly reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 67.7% during the third quarter, now owning 123,250 shares valued at $2.95 million. This reduction could indicate a shift in investor sentiment for the San Diego-based biopharmaceutical company, which focuses on developing therapies for rare kidney and genetic disorders. The future performance of Travere Therapeutics will depend on its pipeline success and regulatory approvals.
Royce & Associates LP Reduces Stock Position in Travere Therapeutics, Inc. $TVTX
Royce & Associates LP significantly reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 67.7% in the third quarter, selling 257,747 shares and holding 123,250 shares valued at $2.95 million. Other institutional investors like Arizona State Retirement System and Prudential Financial Inc. also adjusted their holdings. The article also notes recent insider sales by Peter Heerma and Christopher R. Cline, Travere Therapeutics' stock performance, and recent analyst ratings.
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX
Vanguard Group Inc. significantly increased its stake in Travere Therapeutics, now holding 6,613,368 shares valued at $158.06 million, representing about 7.39% of the company. Analysts have a "Moderate Buy" consensus rating for TVTX with an average price target of $38.17. Despite some institutional selling, insider ownership remains at 4.06%.
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector
Travere Therapeutics (NASDAQ: TVTX), a biopharmaceutical company focusing on rare kidney and metabolic diseases, shows a potential upside of 44.65% according to analyst ratings. Despite current financials reflecting a growth-phase biotech firm with negative EPS and ROI, its strong revenue growth and promising pipeline, including treatments for IgA Nephropathy and cystinuria, position it for future success. The company benefits from strong analyst confidence and its strategic focus on unmet medical needs in rare disease markets.
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX
Legato Capital Management LLC recently purchased 71,030 shares of Travere Therapeutics (NASDAQ:TVTX) for approximately $1.698 million, establishing a new position in the company. Other institutional investors like Stephens Investment Management, Frazier Life Sciences Management, and Perceptive Advisors also made significant acquisitions. Despite insider selling of 311,925 shares valued at $10.62 million in the last quarter, analysts maintain a "Moderate Buy" consensus for TVTX with a target price of $38.17.
